Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL) (“Satellos” or the “Company”), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle...
Satellos Bioscience Inc. (Nasdaq: MSLE , TSX: MSCL ) (“Satellos” or the “Company”), a clinical-stage biotechnology company focused on restoring natural muscle...
Today announced that the first participant has been dosed in BASECAMP, a three-month, randomized, double-blind, ...
BASECAMP, a three-month, randomized, double-blind, placebo-controlled study, will evaluate SAT-3247’s safety and tolerability, and effect on muscle force, muscle quality and muscle regeneration
Satellos Bioscience Inc. (Nasdaq: MSLE , TSX: MSCL ) (“Satellos” or the “Company”), a clinical-stage biotechnology company focused on restoring natural muscle...
Satellos Bioscience Inc . (Nasdaq: MSLE, TSX: MSCL) (“Satellos” or the “Company”), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle...
BASE SHELF PROSPECTUS IS ACCESSIBLE, AND PROSPECTUS SUPPLEMENT WILL BE ACCESSIBLE WITHIN TWO BUSINESS DAYS ON SEDAR+
BASE SHELF PROSPECTUS IS ACCESSIBLE, AND PROSPECTUS SUPPLEMENT WILL BE ACCESSIBLE WITHIN TWO BUSINESS DAYS ON SEDAR+
Announced the appointment of Antoinette Paone as Chief Development Officer and Head of Regulatory Affairs. ...
Experienced industry leader brings extensive expertise in leading breakthrough therapies through clinical development to marketing approval